Website Notice Block

Press Releases

Date Title and Summary View
Toggle Summary NexoBrid® Highlighted in 39 Presentations at the 18th European Burns Association Congress in Helsinki
YAVNE, Israel , Sept. 03, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound care management, today announced a significant presence at the 18 th European Burns
View HTML
Toggle Summary MediWound Reports Second Quarter 2019 Financial Results
Total revenues of $20.7 million , driven primarily by the upfront payment from Vericel for NexoBrid ® license agreement BARDA committed additional $21 million to fund NexoBrid ® expanded access treatment protocol Confirmed BLA submission plans in a pre-BLA meeting with FDA Company to initiate an
View HTML
Toggle Summary MediWound to Report Second Quarter 2019 Financial Results and Host a Conference Call and Webcast on August 13
YAVNE, Israel , Aug. 06, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the second
View HTML
Toggle Summary MediWound Launches EscharEx® U.S. Clinical Development Program
Company’s primary focus turns to EscharEx following its successful collaboration for NexoBrid Company to initiate an adaptive comprehensive adequately controlled study in 4Q 2019 Company to host Analyst Day today, July 22 , in New York, NY YAVNE, Israel , July 22, 2019 (GLOBE NEWSWIRE) -- MediWound
View HTML
Toggle Summary MediWound to Host Analyst Day on its Innovative Product EscharEx® for Debridement of Chronic Wounds
YAVNE, Israel , July 16, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, will host an analyst day on its innovative product for chronic wounds on Monday,
View HTML
Toggle Summary MediWound Appoints Mr. Boaz Gur-Lavie as Chief Financial Officer
YAVNE, Israel , June 11, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the appointment of Mr.
View HTML
Toggle Summary NexoBrid® Receives Marketing Authorization from Peru’s Ministry of Health
Avalon Pharmaceutical Peru S.A.C., MediWound’s exclusive distributor, plans commercial launch for first half of 2020 YAVNE, Israel , June 04, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in
View HTML
Toggle Summary BARDA Upsizes Support for NexoBrid with an Additional $21 Million to Fund Continuous Access Treatment Protocol for Thermal Burn
Total non-dilutive funds for NexoBrid now valued at up to $196 Million MediWound to initiate NexoBrid expanded access treatment protocol (NEXT) in the third quarter of 2019, allowing for ongoing use of NexoBrid to treat burn patients in U.S. YAVNE, Israel , May 29, 2019 (GLOBE NEWSWIRE) --
View HTML
Toggle Summary MediWound Reports First Quarter 2019 Financial Results
Met Primary and All Secondary Endpoints in Pivotal Phase 3 DETECT Study; NexoBrid BLA Filing Planned for Fourth Quarter of 2019 Signed Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid ® in North America Conference call begins today at 8:30 a.m.
View HTML
Toggle Summary MediWound to Host First Quarter Financial Results Conference Call on May 21at 8:30 a.m. Eastern Time
YAVNE, Israel , May 14, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the first
View HTML